Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027366 | 0.94 | PDPK1 (0.47) | MAPTNPSR1ABCG2ABCB1TDP1 | |
| SCHEMBL7030660 | 0.94 | TDP1 (0.50) | MAPTNPSR1CXCL12ABCG2ABCB1 | |
| SCHEMBL7026784 | 0.93 | ABCB1 (0.49) | MAPTNPSR1CXCL12ABCG2ABCB1 | |
| SCHEMBL7029104 | 0.93 | TP53 (0.43) | MAPTNPSR1CXCL12ABCG2ABCB1 | |
| SCHEMBL7026486 | 0.93 | MAPT (0.53) | MAPTNPSR1ABCB1KCNA3 | |
| SCHEMBL7028278 | 0.91 | ABCB1 (0.51) | MAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL743842 | 0.91 | MAPT (0.48) | MAPTNPSR1CXCL12ABCG2ABCB1 | |
| SCHEMBL7027458 | 0.91 | ABCB1 (0.41) | MAPTNPSR1ABCG2ABCB1TDP1 | |
| SCHEMBL7029021 | 0.90 | ABCB1 (0.46) | MAPTNPSR1ABCG2ABCB1 | |
| SCHEMBL20858990 | 0.90 | MAPT (0.45) | MAPTNPSR1CXCL12ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | MAPT 3525/4885NPSR1 4569/4885CXCL12 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.